

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798

Status	RECRUITING
Phase	Phase 3
Sponsor	Alexion Pharmaceuticals, Inc.
Enrollment	450 participants

Key Eligibility Criteria

Inclusion (5)

- e 18years of age at the time of signing the informed consent
- Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)
- A candidate for kidney transplant from:
 - Donation after Circulatory Death (DCD) donor
 - High-risk Donation after Brain Death (DBD) donor

Exclusion (2)

- Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification
- Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.

Locations (130 total)

Research Site, Phoenix, Arizona, United States
Research Site, Los Angeles, California, United States
Research Site, San Francisco, California, United States
... and 127 more locations